Amplia

Be first to know our latest company updates

Watch exclusive videos accompanying major news

Science

Contact

Board

Company Overview

Team

Corporate Governance

Corporate Directory

Values

Clinical Advisers

About Us

Video Updates

Presentations

In the News

Communication

Updates

US Shareholders

Investor FAQs

Shareholder Services

Research Reports

Reports

Announcements

Investor Fact Sheet

Top 20 Shareholders

Share Price

Investor Centre

Clinical Trial

Webinars

Home

Montserrat

Amplia Therapeutics Limited

upload.jpg

Amplia has announced that the US Patent and Trademark Office (USPTO) has notified the Company that a key patent protecting the Company’s best-in-class FAK inhibitor narmafotinib has been allowed in the US.

The patent, titled A salt and crystal form of a FAK Inhibitor, describes the specific chemical form of narmafotinib being utilised in the current ACCENT and AMPLICITY trials in advanced pancreatic cancer.

The patent allowance precedes the formal ‘Notification of Grant,’ expected in the coming months. This key patent, which has already been granted in Japan, Europe, Australia, India, Korea, Singapore and New Zealand, extends protection for narmafotinib in these regions until at least 2040. Applications in other jurisdictions remain under review.

Amplia’s CEO and Managing Director Dr Chris Burns commented:

“We continue to build a patent portfolio around narmafotinib to ensure the Company’s key intellectual property is protected and thus commercially valuable, for as long as possible.”

Patent allowance for key narmafotinib patent in US 